BRA
VRTX icon

Bender Robert & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bender Robert & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-27,288
Closed -$12.8M – 80
2024
Q2 		$12.8M Buy
+27,288
New +$11.8M 2.81% 11

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bender Robert & Associates's VRTX Position: Q1 2026 in Review

Bender Robert & Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, selling an estimated $136K and leaving 26,171 shares worth $11.7M. The position accounts for 2.8% of the portfolio, ranked #11.

Bender Robert & Associates first reported a position in VRTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $13.1M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bender Robert & Associates held 26,171 shares of Vertex Pharmaceuticals worth $11.7M as of Q1 2026.
  • Bender Robert & Associates sold 292 Vertex Pharmaceuticals shares in Q1 2026, an estimated $136K.
  • Vertex Pharmaceuticals made up 2.8% of Bender Robert & Associates's portfolio in Q1 2026, its #11 holding.
  • Bender Robert & Associates first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Bender Robert & Associates's Vertex Pharmaceuticals position peaked at $13.1M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bender Robert & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.